Teva and Sanofi conclude collaboration deal for anti-TL1A therapy
Teva Pharmaceuticals and Sanofi have concluded a collaboration deal for co-developing and co-commercialising the anti-tumour necrosis factor-like ligand 1A (TL1A) therapy, TEV’574. The therapy is under assessment in Phase IIb clinical studies to treat two types of inflammatory bowel disease (IBD), ulcerative colitis and Crohn's disease. The conditions share symptoms such as rectal bleeding, abdominal pain, persistent diarrhoea, fatigue and weight loss. Approximately ten million people globally are dealing with IBD. In October 2023, the two companies signed an agreement in which Teva will receive an upfront payment of €469m ($500m) and be eligible for milestone-based payments of €940m. The companies will divide global development expenses equally and share net profits and losses in key markets. Additional markets will follow a royalty arrangement, and Sanofi will lead in the Phase III programme development. Teva will be responsible for product commercialisation in regions and countries including Europe and Israel, while Sanofi will manage commercialisation in North America, Japan, other parts of Asia and the rest of the world. The first outcomes of the programme will be revealed in 2024. In November 2023, Teva announced a partnership with Royalty Pharma to expedite a clinical research programme for antipsychotic therapy olanzapine LAI [long-acting injectable] TEV-‘749. Teva will obtain $100m from Royalty Pharma to support olanzapine LAI’s ongoing development costs. On receiving approval from the US Food and Drug Administration, Teva will reimburse the funding, apart from royalty payments, to Royalty Pharma over five years. Olanzapine LAI is an antipsychotic therapy being analysed in a Phase III trial to treat schizophrenia. It is administered once a month as a subcutaneous injection.
Teva and Sanofi have concluded a collaboration deal for co-developing anti-tumour necrosis factor-like ligand 1A (TL1A) therapy, TEV’574.
What's Your Reaction?
